一种基于改性β-葡萄糖的新型全癌细胞疫苗,可以引起强大的抗瘤免疫力
Jianhan Huang1,2,3,4,5, Yuyuan Wang1,2,3,4,5, Junrong Zhu6,7
1Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200000, PR China.
Theranostics
|January 9, 2026
概括
一种新的酵母β-葡萄糖和聚D-氨酸合辅助剂 (G-PL) 增强了自身全瘤细胞疫苗. 这种免疫治疗策略增强了抗瘤免疫力,并改善了多种癌症模型的存活率.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 自主全瘤细胞为个性化癌症疫苗提供广泛的抗原,但由于免疫性较弱,需要辅助剂.
- 辅助剂联合递送系统对于提高基于全瘤细胞的免疫疗法的疗效至关重要.
- 开发有效的辅助剂是释放个性化癌症疫苗潜力的关键.
研究的目的:
- 开发和评估一种用于自身全瘤细胞疫苗的新型合辅助剂 (G-PL).
- 评估辅助剂增强树突细胞 (DC) 激活,免疫启动和抗瘤疗效的能力.
- 研究各种癌症模型中的潜在机制,包括Dectin-1-介导的Th17诱导.
主要方法:
- 联合辅助剂 (G-PL) 是通过将修改的酵母β-葡萄糖与聚D-氨酸结合合成的.
- 辅助细胞复合体 (ICC@G-PL) 是通过用G-PL.覆盖照射的瘤细胞而形成的.
- 评估DC招募/激活,淋巴结原始化,以及在质母细胞瘤,结肠癌和黑色素瘤模型中的治疗疗效.
- 通过Westernblotting和流式细胞计量对Dectin-1-介导的Th17诱导的分析.
主要成果:
- G-PL证明了快速的细胞膜粘附,没有细胞毒性.
- ICC@G-PL增强了体外DC成熟和Th17分化.
- 在体内研究表明,增加了DC招募,淋巴结激活,并增加了益炎性细胞因子 (IL-12,TNF-α,IFN-γ).
- 疫苗显著延长了生存期,增加了内CD8+/CD4+T细胞比率,M1巨细胞和中性粒细胞,与Th17驱动的反应相关.
结论:
- G-PL是一种基于β-葡萄糖的新型辅助剂,可促进自身全细胞疫苗的快速制造.
- 这种策略有效地增强了瘤特异性免疫力,并重新编程了瘤微环境.
- G-PL 方法为个性化癌症免疫疗法提供了一个多功能平台.
相关概念视频
Cancer Vaccines
946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cytotoxic T Cells-mediated Immune Response
6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K


